Pipeline J&J adds rare disease wAIHA to Imaavy’s potential uses PharmaphorumJohnson Johnson's 'Swiss army knife' drug Imaavy has shown efficacy in a pivotal trial involving patients with rare autoimmune disorder wAIHA.Rare DiseaseRead full story pharminent June 11, 2026 (Last updated: June 11, 2026) Pharmaphorum Johnson Johnson’s ‘Swiss army knife’ drug Imaavy has shown efficacy in a pivotal trial involving patients with rare autoimmune disorder wAIHA. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Novartis gets win for another Avidity muscular dystrophy AOCNext: Sky-high Parabilis, Kailera IPOs spur optimism–but only for derisked biotechs Related Stories Pipeline Sanofi drops two more programmes in R&D clear-out pharminent July 30, 2026 Pipeline Lundbeck preps for key bexicaserin data around year-end pharminent July 20, 2026 Pipeline AAIC 2026: Tau-targeted Alzheimer’s treatments heat up while amyloid therapies persist pharminent July 10, 2026
